Significant biosimilar activities this week include: 11 Dec 22 | New study reports glofitamab is effective in diffuse large B-cell lymphoma A new Roche study published in the New...
Generic Partners Pty Ltd v Neurim Pharmaceuticals Ltd [2022] APO 2 Generic Partners Pty Ltd v Neurim Pharmaceuticals Ltd [2022] APO 79Date:Venue:Delegates:14 January 2022, 2...
Significant biosimilar activities this week include: 03 Dec 22 | Alvotech announces changes to share listings and leadership team Alvotech announced that Nasdaq Iceland has...
Significant biosimilar activities this week include: 23 Nov 22 | EU | EMA approves Skyrizi® (risankizumab) for Crohn’s disease AbbVie announced that Skyrizi® (risankizumab) has...
Aristocrat Technologies Australia Pty Limited v Konami Australia Pty Limited (No 3) [2022] FCA 1373 Date:Court:Judge:18 November 2022Federal Court of AustraliaNicholas...
Significant biosimilar activities this week include: 18 Nov 22 | US | FDA approves Rezvoglar® (biosimilar insulin glargine) as interchangeable The FDA approved Eli Lilly’s...
Significant biosimilar activities this week include: 11 Nov 22 | EU | CHMP recommends Dupixent® (dupilimab) for prurigo nodularis The CHMP recommended the approval of Dupixent®...
Significant biosimilar activities this week include: 04 Nov 22 | New dupilumab study suggests serum dupilumab levels are not associated with treatment response or adverse effects...
Significant biosimilar activities this week include: 28 Oct 22 | Health Canada approves additional COVID-19 indication for Actemra® IV (tocilizumab) Roche Canada announced that...
Significant biosimilar activities this week include: 21 Oct 22 | US | Spectrum Pharmaceuticals launched Rolvedon™ Spectrum Pharmaceuticals announced the US launch of Rolvedon™...
Significant biosimilar activities this week include: 14 Oct 22 | BioFactura’s biosimilar ustekinumab shows comparable PK to Stelara® in Ph I trial BioFactura has announced...
Australian Mud Company Pty Ltd v Globaltech Corporation Pty Ltd & Ors (No 3) [2022] FCA 1189 Date:Court:Judge:6 October 2022Federal Court of AustraliaRofe...
We are thrilled to announce that Pearce IP’s founder Naomi Pearce, Executive Lawyer, Patent Attorney and Trade Mark Attorney has been recognised by WIPR as a Diversity Champion...
Significant biosimilar activities this week include: 08 Oct 22 | US | Samsung to pursue adalimumab interchangeability in the US In an interview with Managed Healthcare, Samsung...
We are excited to announce that Pearce IP is a finalist in the Lawyers Weekly Women in Law Awards in the category of 2022 Boutique Diversity firm of the Year. The Women in Law...
Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92Pharmacia LLC v Juno Pharmaceuticals Pty Ltd (No 2) [2022] FCA 369Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022]...
Significant biosimilar activities this week include: 30 Sep 22 | EU | EMA accepts Biogen tocilizumab MAA Biogen announced that the EMA has accepted the MAA for BIIB800...
Sanofi v Amgen Inc. [2022] APO 67Date:Venue:Delegate:26 September 2022Australian Patent OfficeSophina CalanniBackground The five patent applications the subject of these...
PiPCast™ | Expedited Patent Prosecution in Australia and New Zealand
The Australian High Court will have an experienced intellectual property judge on its bench, with the appointment of Justice Jayne Jagot to the bench announced on Thursday 29...
Significant biosimilar activities this week include: 22 Sep 22 | CH | STADA launches Alvotech’s Hukyndra® (100mg/mL adalimumab) in Switzerland Alvotech and STADA announced the...
Pearce IP is very proud to announce that its CEO and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been honoured as the 2022 Patent Lawyer of the...
Significant biosimilar activities this week include: 07 Sep 22 | Celltrion’s ustekinumab biosimilar Ph III trials Yonhap News Agency reported that Celltrion’s ustekinumab...
In this PiPCast®, Naomi Pearce walks through the key IP strategies biosimilars companies are using to enable market entry globally, and canvas biosimilar litigation in Australian courts. They also discuss recent litigation settlement activity and lessons learnt.
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
